Immunotherapy Strategies for Non-Small Cell Lung Cancer
Author Information
Author(s): Kuhlman Justin J., Li Shenduo, Manochakian Rami, Lou Yanyan, Zhao Yujie, Normanno Nicola
Primary Institution: Mayo Clinic, Jacksonville, FL, US
Hypothesis
Can immunotherapy improve outcomes in patients with non-small cell lung cancer undergoing surgery?
Conclusion
Immunotherapy has shown significant benefits in the management of non-small cell lung cancer, particularly in neoadjuvant, perioperative, and adjuvant settings.
Supporting Evidence
- Immunotherapy has been shown to improve overall survival in patients with resectable non-small cell lung cancer.
- Combination therapies involving immunotherapy and chemotherapy have demonstrated higher pathological response rates.
- FDA approvals for immunotherapy in lung cancer have been based on significant survival benefits observed in clinical trials.
Takeaway
This study looks at how new medicines called immunotherapies can help people with lung cancer before and after surgery.
Methodology
The review summarizes data from key studies and discusses treatment strategies for resectable non-small cell lung cancer.
Potential Biases
Potential biases in trial designs and patient selection may affect the generalizability of the findings.
Limitations
The study highlights the need for more data to guide treatment decisions and the challenges in identifying which patients benefit most from immunotherapy.
Participant Demographics
The study includes patients with resectable stage II and III non-small cell lung cancer.
Statistical Information
P-Value
0.0451
Confidence Interval
95% CI 0.47–1.07
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website